Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

byBenzinga Newsdesk

October 13, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today

By Benzinga Insights

Today, 6:59 AM

Air Products & Chemicals (NYSE:APD) has outperformed the market over the past 10 years by 1.27% on an annualized basis producing an average annual return of 12.18%. Currently, Air Products & Chemicals has a market capitalization of $51.95 billion.

APD

Exclusive: Start-Up Offers Copper Paste As A Cost-Effective Alternative To Silver In Solar Panels

By Phil Hall

Today, 6:59 AM

Within the solar power industry, silver is a crucial material within the manufacturing of photovoltaic panels. Silver is turned into a paste that is loaded into the silicon wafers within the panel.

SPY

Barclays Initiates Coverage On Outbrain with Overweight Rating, Announces Price Target of $25

By Benzinga Newsdesk

Today, 6:59 AM

Barclays analyst Ross Sandler initiates coverage on Outbrain (NASDAQ:OB) with a Overweight rating and announces Price Target of $25.

Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate

By Ragothaman Srinivasan

Today, 6:59 AM

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome.

ACAD

Oppenheimer Downgrades Relmada Therapeutics to Perform

Related Posts

$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today

Exclusive: Start-Up Offers Copper Paste As A Cost-Effective Alternative To Silver In Solar Panels

Barclays Initiates Coverage On Outbrain with Overweight Rating, Announces Price Target of $25

Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate